Literature DB >> 2488049

Influence of thymic preparations on the result of experimental infection with Taenia crassiceps (Zeder, 1800) in ICR mice.

J Hermánek1, J Prokopic.   

Abstract

Thymalin (Thymarin) and T-activin--thymic preparations of polypeptidic character--were used for influencing the parasitic infection in a model system mouse--Taenia crassiceps. A single subcutaneous application of 100 micrograms of Thymalin per mouse at the day of infection resulted in a decrease (by 54.9%) in the number of cysticerci in peritoneal cavity of experimental mice compared with the controls. Administration of Thymalin with T. crassiceps larval homogenate at various intervals before and after infection resulted in a statistically significant increase of the level of specific antibodies in the serum of infected mice, this increase, however, did not correlate with the corresponding protective effect. Immunosuppressant azathioprine, injected subcutaneously from 7th to 3rd day preceding infection at a dose of 100 micrograms resulted in a significant increase in the number of T. crassiceps larvae in the peritoneal cavity of experimental mice compared with the controls (by 48.7%). T-activin, injected subcutaneously to mice, immunosuppressed by azathioprine, led to a restoration of resistance of mice to T. crassiceps infection. Subcutaneous application of T-activin alone had a significant protective effect (decrease in cysticerci number by 53.7% in comparison with the controls). Correlation of the level of specific antibodies in the serum of infected mice, value of spleen index and number of T. crassiceps cysticerci in peritoneal cavity of mice was not detected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2488049

Source DB:  PubMed          Journal:  Folia Parasitol (Praha)        ISSN: 0015-5683            Impact factor:   2.122


  1 in total

1.  The initial immune response during experimental cysticercosis is of the mixed Th1/Th2 type.

Authors:  S A Toenjes; R E Kuhn
Journal:  Parasitol Res       Date:  2002-12-17       Impact factor: 2.289

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.